(lp0
S"Celgene Corporation's  Management Presents at Barclays Global Healthcare ... Seeking Alpha - Mar 15, 2017 Okay, welcome to the second day of the Barclays Global Healthcare Conference. My name is Geoff Meacham. I'm the Senior Biopharma Analyst."
p1
aS'Celgene: In Breakout Mode? Seeking Alpha - Mar 16, 2017 Biotech stalwart Celgene touched $140 in the early summer of 2015 just before a bear market swept over the biotech sector. With sentiment on this area of the market improving and this biotech juggernaut continuing to execute, shares touched a one year&nbsp;...'
p2
aS"Celgene: A Growth Stock You Don't Want To Miss Seeking Alpha - Mar 10, 2017 The company operates in more than 60 countries and sells its products in more than 70. In 2016, Celgene generated sales of $11.2 billion."
p3
aS"Celgene Corp Presents Cowen Health Care Broker Conference   Seeking Alpha - Mar 8, 2017 Good morning, everyone. My name is Eric Schmidt, and on behalf of the Cowen team I want to welcome you back to our 37th Annual Healthcare Conference, day three.Celgene Adds To Wednesday's Gain - Benzinga"
p4
aS"Celgene: A 'Fuggedaboutit' Core Biotech Holding Seeking Alpha - Feb 23, 2017 Few large-cap biotech concerns have a clearer earnings and revenue growth trajectory over the next 3-5 years than Celgene. It has a blockbuster blood cancer drug, several other solid compounds in its product portfolio, a deep pipeline, and dozens of&nbsp;..."
p5
aS'The company addressed these topics at a Cowen and Company healthcare ... Seeking Alpha - Mar 10, 2017 In addition, CELG laid out a simplified list of its pipeline drugs by date and sales potential that may assist investors in their understanding of its plans.Celgene Co.  Downgraded by Zacks Investment Research to Hold - Sports Perspectives'
p6
aS'Celgene Corporation  Stock Is Staging a Tempting Breakout Investorplace.com - Mar 10, 2017 If there was ever a doubt, the latest price action in Celgene Corporation  should help ease those fears and usher in more investor cheer in the coming weeks.'
p7
aS"Celgene Announces Oral OTEZLA Demonstrated Significant Improvement vs Placebo ... Benzinga - Mar 5, 2017 Celgene Corporation  today announced that results from its phase 4 UNVEIL trial evaluating OTEZLA , the Company's oral, selective inhibitor of phosphodiesterase 4 , in patients with moderate plaque psoriasis with a&nbsp;..."
p8
aS"Reliable stocks in today's share market: Celgene Corporation  The News Journal - 11 minutes ago The market cap of 97845.28 for Celgene Corporation in today's market indicated its current strength, making the company's shares a lucrative one.What are Analyst's Indicators for Celgene Corporation , Mylan NV  - The USA CommerceChecking the Overall Picture for Celgene Corporation  - StockNewsJournal"
p9
aS'An intrinsic value calculation for Celgene Corporation  shows investors ... Simply Wall St - Mar 6, 2017 Does the March share price for Celgene  reflect its intrinsic value? I am going to calculate it now using a method called discounted cash flow or DCF.'
p10
a.